The Company
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Contact
Office
Investors
Media
Svenska
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Office
Investors
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Erik Magnusson
Chief Financial Officer (CFO)
+46 70 856 52 45
Press Releases
All press releases
Regulatory press releases
Non-regulatory press releases
2023
2022
2021
2020
2019
2018
2017
2016
2015
2013
All years
September 18, 2023
NOTICE OF EXTRAORDINARY GENERAL MEETING PROMORE PHARMA AB (PUBL)
August 30, 2023
Interim report January – June 2023
August 16, 2023
Promore Pharma engages Erik Penser Bank as liquidity provider
June 27, 2023
Report from the Annual General Meeting of Promore Pharma AB held on 27 June 2023
June 22, 2023
Promore Pharma reduces costs and explores the conditions for a reverse acquisition
May 25, 2023
Promore Pharma’s AGM related Documents Published
May 23, 2023
Interim report January – March 2023
May 9, 2023
Promore Pharma’s Annual Report 2022
April 20, 2023
Promore Pharma AB changes the AGM date to June 27
April 20, 2023
Invitation to a presentation of the results from Promore Pharma’s clinical trial PHSU05
April 20, 2023
Promore Pharma reports outcome from clinical Phase II study with ensereptide
February 28, 2023
Year-end report, 2022
February 27, 2023
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Fourth Quarter 2022
February 27, 2023
Promore Pharma reaches the Clean File milestone in its phase II clinical trial with ensereptide
